Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a rapidly
unfolding pandemic, overwhelming health care systems worldwide 1. Clinical manifestations …

Respiratory tract infection with SARS-CoV-2 results in varying immunopathology underlying
COVID-19. We examine cellular, humoral and cytokine responses covering 382 immune …

While some individuals infected by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) present mild-to-severe disease, many SARS-CoV-2-infected individuals are …

SARS-CoV-2 is a new beta coronavirus, similar to SARS-CoV-1, that emerged at the end of
2019 in the Hubei province of China. It is responsible for coronavirus disease 2019 (COVID …

Abstract COVID-19 is associated with 5.1% mortality. Although the virological,
epidemiological, clinical, and management outcome features of COVID-19 patients have …

More than one year since its emergence, corona virus disease 2019 (COVID-19) is still
looming large with a paucity of treatment options. To add to this burden, a sizeable subset of …

Background Both humoral and cell-mediated responses are associated with immunity to
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our …

Cellular and humoral immunity to SARS-CoV-2 is critical to control primary infection and
correlates with severity of disease. The role of SARS-CoV-2-specific T cell immunity, its …

The precise interaction between the immune system and severe acute respiratory syndrome
coronavirus 2 (SARS‑CoV‑2) is critical in deciphering the pathogenesis of coronavirus …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) can trigger a cytokine
storm in the pulmonary tissue by releasing various types of mediators, leading to acute …